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Most extracellular proteins are secreted via the classical endoplasmic reticulum
(ER)/Golgi-dependent secretion pathway; however, some proteins, including a few
danger-associated molecular patterns (DAMPs), are secreted via non-classical
ER/Golgi-independent secretion pathways. The evolutionarily conserved high mobility
group box1 (HMGB1) is a ubiquitous nuclear protein that can be released by almost
all cell types. HMGB1 lacks signal peptide and utilizes diverse non-canonical secretion
mechanisms for its extracellular export. Although the post-translational modifications
of HMGB1 were demonstrated, the oxidation of HMGB1 and secretion mechanisms
are not highlighted yet. We currently investigated that peroxiredoxins I and II (PrxI/II)
induce the intramolecular disulfide bond formation of HMGB1 in the nucleus. Disulfide
HMGB1 is preferentially transported out of the nucleus by binding to the nuclear
exportin chromosome-region maintenance 1 (CRM1). We determined the kinetics of
HMGB1 oxidation in bone marrow-derived macrophage as early as a few minutes after
lipopolysaccharide treatment, peaking at 4 h while disulfide HMGB1 accumulation was
observed within the cells, starting to secrete in the late time point. We have shown
that HMGB1 oxidation status, which is known to determine the biological activity in
extracellular HMGB1, is crucial for the secretion of HMGB1 from the nucleus. This review
summarizes selected aspects of HMGB1 redox biology relevant to the induction and
propagation of inflammatory diseases. We implicate the immunological significance and
the need for novel HMGB1 inhibitors through mechanism-based studies.
Keywords: high mobility group box1 (HMGB1), oxidation, inflammation, therapeutic target, danger-associated
molecular pattern (DAMP)
INTRODUCTION
High mobility group box 1 (HMGB1) is an abundant non-histone nuclear protein that was
discovered over four decades ago. The protein was isolated from calf thymus chromatin by 0.35M
NaCl extraction (1) and was then biochemically characterized (2). Based on its mobility during
polyacrylamide gel electrophoresis, Goodwin et al. termed the proteins “high mobility group,” or
HMG proteins; however, the group of proteins that migrated more slowly during polyacrylamide
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gel electrophoresis were termed “low-mobility group” proteins.
HMG proteins were therefore divided into two groups based
on their molecular weight: higher—HMG-1 and HMG-2 (now
HMGB1 and HMGB2), lower—HMG-14 and HMG-17 (now
HMGN1 and HMGN2), and HMG-I, -Y (now HMGA1a and
HMGA1b) (3–9).
HMG proteins are categorized into three superfamilies
based on the specific functional domains or motifs via
which they recognize individual DNA structures on chromatin:
HMGA, HMGB, and HMGN. Proteins in the HMGA family
contain an AT-hook, which is a DNA-binding motif with a
preference for A/T rich regions. In contrast, those in the
HMGB family contain A-box and B-box functional motifs
and those in the HMGN family contain a nucleosomal
binding domain (NBD). HMGB proteins are ubiquitous and
abundant in most cells and can bind to DNA without sequence
specificity (10–12).
The human HMGB1 protein has 215 amino acid (aa) residues
(MW: 25–30 kDa) that form two homologous DNA-binding
domains (A-box, 1–79 aa; B-box, 89–162 aa) and a negatively
charged C-terminal acidic tail (186–215 aa; Figure 1A) (9, 13).
HMGB1 is located in the nucleus as a result of bipartite
nuclear localization signals (NLS; NLS1, 28–44 aa; NLS2, 179–
185 aa) mediated by the nuclear importin karyopherin (KAP)-
α1; however, the affinity between the two molecules is decreased
by HMGB1 phosphorylation (14, 15). Conversely, the DNA-
binding domain of HMGB1 contains a nuclear-export signal
(NES), and its cytoplasmic localization is mediated by the
nuclear exportin chromosome-region maintenance 1 (CRM1)
(16). The acidic C-terminal of HMGB1 regulates DNA binding
and bending by interacting with its DNA-binding domains
(8, 17) or histones H1/H3 (18); thus, HMGB1 lacking the C-
terminal domain displays improved DNA looping and binding
abilities (19).
The C-terminal acidic domain of HMGB1 also functions
as a transcriptional activator (20, 21), while HMGB1 B-box
has been reported to induce pro-inflammatory signals upon
extracellular stimulation, and the A-box induces antagonistic
effects (22). In particular, the 201–205 aa residues in the C-
terminal acidic tail play a crucial role in the antibacterial
activity of HMGB1 (23). Moreover, interactions with diverse
receptors, extracellular partners, and intracellular partners play
important roles in the activity and biological functions of
HMGB1. HMGB1 residues 89–108 bind to Toll-like receptor
(TLR) 4 and increase pro-inflammatory signaling (22), whereas
residues 150–183 interact with the receptor for advanced
glycation end products (RAGE) to regulate cell migration
(24) and stimulate inflammation (25). HMGB1 has also been
shown to bind to dendritic cell (DC)-derived TIM-3 and
suppress nucleic acid-mediated innate immune responses (26).
In addition, residues 1–15 and 80–96 have been found to
inhibit lipopolysaccharide (LPS)-induced cytokine production in
a subclinical endotoxemia mouse model (27). HMGB1 binds to
lipoteichoic acid (LTA) and enhances proinflammatory responses
by mediating the transfer of LTA to CD14 and TLR2 (28).
Furthermore, HMGB1 residues 6–12 are responsible for binding
heparin and compete with binding between RAGE and HMGB1
(29). A- and B-box of HMGB1 bind to C1q, but only B-box of
HMGB1 can induce the complement activation leading to sterile
inflammation (30). In addition, complex formation between
HMGB1 and IL-1β enhances inflammation and destruction
mechanisms in arthritic joints (31), whereas the HMGB1 and
C-X-C motif chemokine ligand 12 (CXCL12) complex binds
to C-X-C chemokine receptor 4 (CXCR4) and promotes the
recruitment of inflammatory cells (32). Extracellular HMGB1
binds to single-stranded oligonucleotides, forming HMGB1-5’-
C-phosphate-G (CpG)-DNA complex, interacting with TLR9
to augments cytokine production (33, 34). Also, HMGB1
released from apoptosis binds to the nucleosomes and induces
cytokine production or dendritic cells (DCs) activation through
interaction with TLR2 (35). In contrary, HMGB1-CD24 complex
selectively represses the tissue damage-induced inflammation via
interaction with Siglec-10 protein (36). Cytoplasmic HMGB1
binds to Beclin 1 using intramolecular disulfide bridge (Cys23
and Cys45) to affect autophagosome formation (37). Cys23 or
Cys45 in HMGB1 can also bind to reactive cysteine residues in
peroxiredoxins I and II (PrxI/II) to form intramolecular disulfide
bonds that promote its secretion in response to inflammatory
stimuli (38). Residues 7–74 are responsible for binding the p53
transactivation domain and thus increasing gene transcription
(39) (Figure 1A).
Studies have modified HMGB1 A-box and B-box structures
using the PyMol program based on 2YRQ [Protein Data Bank
(PBD) ID: 2yrq]. These two DNA-binding domains consist of
three alpha helices (helix-I, -II, and -III) and two loops (loop-
I and -II) that form an L-shaped structure (40). HMGB1 binds
to the minor groove of pre-bent or linear DNA with little
sequence specificity (41, 42); however, both A- and B-box have
the remarkable ability to unwind and bend DNA with different
properties. For instance, the A-box domain recognizes pre-
bent or linear DNA, whereas the B-box domain binds to mini-
circles and bends linear DNA (43–45). In the crystal structure of
HMGB1 showing A-box domains and an AT-rich DNA fragment,
the two HMGB1 A-box domains were found to collaborate in
order to interact with pre-bent or kinked DNA. The Phe37
(Phe38 in HMGB1 described here) residues from both domains
were shown to play important roles in initiating intercalation
with CG base pairs and thus generating highly kinked DNA
(Figure 1B) (46). The B-box domain is structurally similar to
the A-box in its DNA-binding characteristics and its Ile34 (Ile35
in B-box or Ile122 in the full HMGB1 sequence described here)
residue is sterically comparable to the Phe37 residue in the A-box
domain (Figure 1B).
HMGB1 senses and coordinates the cellular stress response.
As mentioned earlier, HMGB1 contains three conserved
cysteines: Cys23, Cys45, and Cys106 (Figure 1A). Cys23 and
Cys45 can form an intramolecular disulfide bond depending
on the reactive oxygen species (ROS) concentration and
environmental conditions under which HMGB1 binds to its
ligands (Figure 1C) (47). Indeed, the half-life of all-thiol-
HMGB1 ranges from ∼17min in human serum and saliva to
3 h in cell culture medium (47). The oxidation state of HMGB1
determines its interactions with diverse receptors (32, 48) and
its DNA-binding affinity (49). Depending on its redox status,
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FIGURE 1 | Structure of HMGB1. (A) Detailed summary of various domains and motifs in HMGB1. (B) Signature L-loop structure of the A-box and B-box structures
of HMGB1. (C) Overall structure of HMGB1 showing the functional A-box cysteines (C23 and C45) and their geometric distribution in HMGB1. A-box and B-box
structures modified based on 2YRQ [Protein Data Bank (PDB) IP: 2yrq] using PyMol. NLS, nuclear localization sequence; NES, nuclear export signal; TLR4, toll-like
receptor 4; RAGE, receptor for advanced glycation endproducts; Tim-3, T-cell immunoglobulin and mucin domain-containing protein-3; LPS, lipopolysaccharide; LTA,
lipoteichoic acid; C1q, complement component 1q; IL-1β, interleukin 1β; CXCL12, C-X-C motif chemokine 12; F, phenylalanine; I, isoleucine; C, cysteine; C-term,
C-terminal; N-term, N-terminal. Solid line; known binding domain or sequence of HMGB1, Dotted grey line; unknown sequence of HMGB1.
extracellular HMGB1 can trigger numerous effects: (1) all-
thiol-HMGB1 can exert chemoattractive effects by binding to
CXCR4; (2) all-thiol-HMGB1 can prompt autophagy by binding
to RAGE (50); (3) disulfide-HMGB1 can exert pro-inflammatory
effects by binding to TLR4; and (4) fully oxidized-HMGB1
is inert. Cys106 plays a crucial role in the translocation of
HMGB1 from the nucleus to the cytosol (51). Moreover, C23-
C45 oxidation induces a shift between helix I and helix II in the
A-box domain that reduces DNA binding affinity by altering the
orientation of Phe37 (52), resulting in cytoplasmic translocation.
HMGB1 can also affect transcription in the nucleus, requiring
rapid transition between the all-thiol-and disulfide forms
of HMGB1 (53).
Purification of HMGB1 under its native conditions yields
both homodimers and oligomeric forms of the protein; however,
these forms are dissociated when acid-extracted (54). Our
group has also described the Cys106-mediated formation of
HMGB1 dimers under conditions of excessive ROS generation
at the cellular level (unpublished data). As previously discussed,
HMGB1 is a versatile molecule because of intra- and inter-
molecular interactions in its different domains; moreover, the
protein can be either actively secreted by activated immune
cells or passively released due to necrotic cell death where
it acts as a damage-associated molecular pattern (DAMP).
Because of its versatile and variable nature, it is important
to understand the mechanism underlying the secretion of
HMGB1 to fully appreciate its therapeutic and pathological
potential. In this review, we briefly summarize the conventional
and non-conventional mechanisms of cytokine secretion, and
describe in detail the mechanisms of HMGB1 oxidation and
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Most soluble secretory proteins utilize a well-known
conventional secretion system involving the endoplasmic
reticulum (ER) and Golgi network, and contain a signal peptide
to target them to the ER (55).When such proteins are synthesized
in the ribosome, the signal peptide is recognized by a signal
recognition particle (SRP) complex. The protein-ribosome-SRP
complex then moves to the Sec61 translocon complex in the ER
outer membrane and proteins translocate into the ER lumen
via the translocon complex (56, 57). Within the ER lumen, the
protein meets chaperone proteins such as Bip and undergoes
modification (glycosylation) followed by protein folding (58, 59).
These proteins are then translocated to the Golgi and plasma
membrane via several processes, concluding the conventional
protein secretion pathway. A recent study found that when
the ER/Golgi pathway is blocked, some proteins are secreted
via an independent mechanism. These proteins lack a signal
peptide targeting them to the ER and are secreted under specific
conditions, such as ROS accumulation, inflammation, and cell
growth factors. These forms of protein secretion are considered
unconventional, and the secreted proteins are generally involved
in immune surveillance, cell survival, and cellular stress (60).
Cytokines regulate immunological functions via their
secretion in immune environments; therefore, controlling
cytokine secretion is crucial for regulating immune function.
Many cytokines such as tumor necrosis factor-α (TNF-α),
interleukin (IL)-2, and IL-12 are secreted via the conventional
secretion mechanism; however, some, including HMGB1, IL-1β,
fibroblast growth factor (FGF)-1/2, and galectins, utilize non-
conventional secretion mechanisms. Here, we briefly explore
different cytokines that use various secretion mechanisms, and
summarize them in Table 1.
Tumor Necrosis Factor (TNF)-α
TNF-α was first identified for its anti-tumor activity but is
now also known to act as a multifunctional cytokine in host
defense mechanisms during inflammatory responses (77). Since
it contains an ER signal peptide, TNF-α is translocated across the
ER and through the Golgi apparatus to the plasma membrane
(61). Newly synthesized TNF-α is localized in the trans-Golgi
network (TGN) with golgin and p230/golgin-245 for intracellular
trafficking and cell surface delivery (78). TNF-α is then released
from the granule via fusion with the plasma membrane (62)
and is cleaved at the cell surface by the tumor necrosis factor-α
converting enzyme (TACE) between Ala76 and Val77 (79).
Interleukin (IL)-1β
IL-1β plays important roles in the cytokine response to
inflammation and immunity during bacterial or viral infection
and is mainly secreted by monocytes, macrophages, and CD
in response to inflammasome activation under conditions such
as LPS and adenosine triphosphate (ATP) stimulation (80).
Although IL-1β is passively released during pyroptotic cell death
(63), secretion of cleaved-IL-1β requires cytosolic compartments
such as the secretory lysosome (64), microvesicles shed from the
plasmamembrane (81) or exosomal release (65). Previous studies
have reported that caspase-1/11 cleave gasdermin D (GSDMD),
whose N-terminal then forms pores in the plasma membrane
that are crucial for the passive release of IL-1β during pyroptosis
(66, 67). Although the pathway is unknown, IL-1β secretion
is known to require ABC transporters whose knockdown or
inhibition is reported to ameliorate IL-1β secretion (82, 83).
Fibroblast Growth Factor (FGF) -1 and -2
FGF-1 and -2 belong to a family of heparin-binding growth
factors (84) and control mitogenic activity (85) and tumor-
induced angiogenesis (86). FGF-1/2 are not only secreted via
the ER/Golgi-dependent secretion pathway, but also the non-
conventional secretion system (68–70); however, the secretion
pathways of FGF-1 and FGF-2 are distinct (87). Unlike FGF-1,
FGF-2 secretion is sensitive to Na+/K+-ATPase inhibition and
is dependent on forming higher-order complexes with Na+/K+-
ATPase ion transporters, with its export occurring in amembrane




TNF-α Conventional - Translocated across the ER and through the Golgi apparatus to the plasma membrane (61, 62)
IL-1β Non-conventional - Secretion by secretory lysosome, microvesicles shed, or exosome




- FGF-1/2 are not only secreted via the conventional secretion pathway, but also the
non-conventional secretion system
FGF-1
- Secretion is increased by cellular stresses such as heat shock, hypoxia, and
serum starvation
FGF-2
- Dependent on forming complexes with Na+/K+-ATPase
(68–73)
Galectins Non-conventional - Accumulate at the plasma membrane and induce the formation of exosomes pinched off
and released into extracellular space
(74–76)
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potential-independent manner (71). Conversely, FGF-1 secretion
is increased by cellular stresses such as heat shock (88), hypoxia
(72), and serum starvation (73), while copper also can induce
FGF-1 secretion by forming multiprotein aggregates in response
to stress (89); however, FGF1 folding does not prevent its
export (90).
Galectins
Galectins are a family of abundant β-galactoside-specific lectins
that reside in the extracellular matrix and are implicated in
many cellular processes, such as proliferation, differentiation, and
apoptosis (91, 92). Since galectins lack the signal peptides found
in IL-1β and FGF-1/2 for ER/Golgi-mediated secretion, their
secretion is not blocked by the ER/Golgi-dependent inhibitors
brefeldin A and monensin (74, 93). Moreover, galectin-1/3 are
not packaged into vesicles during extracellular export (74, 75,
94, 95) but accumulate at the plasma membrane and induce the
formation of exosomes that are pinched off and released into
extracellular space (74, 75, 94, 95). Secreted galectins bind to
the extracellular surface of the plasma membrane or extracellular
matrix (75, 76) via the N- and O-glycosylated β-galactose-
terminated oligosaccharide side chains of glycoproteins (74, 92).
HMGB1 SECRETION
Generally, cytokines containing a leader sequence undergo
secretion via the ER/Golgi secretion pathway; however, the non-
histone nuclear protein HMGB1 lacks this signal peptide, and
studies have suggested that HMGB1 secretion involves diverse
unconventional secretion pathways. For instance, infection or
cellular stress has been shown to increase the cytoplasmic
accumulation of HMGB1, which is then passively released into
the extracellular space or actively secreted via secretory lysosomes
(9) (Figure 2). Here, we describe in detail the mechanisms that
participate in HMGB1 secretion.
Passive Release of HMGB1
HMGB1 can be passively released during various forms
of cell death, including pyroptosis, apoptosis, autophagy,
necroptosis, and necrosis (Figure 2A). Pyroptosis refers
to inflammatory programmed cell death that occurs after
inflammasome formation caused by bacterial or viral infection.
During pyroptosis, double-stranded RNA-dependent protein
kinase (PKR) induces inflammasome formation, caspase-1
activation, and HMGB1 release upon exposure to diverse
inflammasome-activating agents (96). Apoptosis is another form
of programmed cell death that occurs when cells die due to
injury and involves caspase-3/7, which belong to a family of
protease enzymes. Apoptotic cells induce HMGB1 release, and
it has been reported that Z-VAD, a pan-caspase inhibitor, can
reduce the levels of HMGB1 released (97). Autophagy is an
intracellular degradation system that balances energy sources
in response to nutrient stress by regulating the degradation of
cellular material using lysosomes or vacuoles; however, excessive
autophagy can lead to cell death. Indeed, studies have shown that
epithelial and glioblastoma tumor cells release HMGB1 when
treated with the autophagy-inducing agent epidermal growth
factor receptor-targeted diphtheria toxin (DT-EGF) (98), also
ATG5 knock-out bone marrow-derived macrophages (BMDMs)
reduced HMGB1 secretion under EBSS starvation conditions
(99). In addition, autophagosome-mediated HMGB1 secretion
has been identified, with ATG5 deficient cells or those treated
with an early autophagy inhibitor displaying all-thiol-HMGB1
secretion (data not published). Necrosis is a form of premature
cell death caused by the loss of membrane integrity, intracellular
organelle swelling, and ATP depletion, and it has been shown
that HMGB1 is passively released by necrotic or damaged cells
(100). Necroptosis is a form of programmed necrosis mediated
by death signals that cause the phosphorylated mixed lineage
kinase domain-like protein (MLKL) to be inserted into and
permeabilize the plasma membrane (101). Moreover, TNF-α/Z-
VAD-induced necroptosis has been shown to phosphorylate
MLKL proteins and increase HMGB1 secretion levels (102).
Post-Translational Modifications (PTMs)
and Active Secretion of HMGB1
HMGB1 can undergo several extensive PTMs that increase
its cytoplasmic accumulation and extracellular secretion
during infection or cell stress, including acetylation (16),
phosphorylation (14, 15), ADP-ribosylation (103), methylation
(104), glycosylation (105), and oxidation (38, 51) (Figure 2B).
Various PTMs increase the interaction between HMGB1 and the
nuclear transport receptor CRM1, thus favoring its translocation
from the nucleus to the cytoplasm. PTM-mediated HMGB1
secretion is caused by lysosomal exocytosis wherein cytoplasmic
HMGB1 co-localizes with the lysosomal marker LAMP1 for
secretion (106). The PTMs and subsequent events that HMGB1
undergoes are summarized below and visualized in Figure 2B.
1) Acetylation is a major PTM that can affect protein function
by altering properties such as hydrophobicity, solubility, and
surface properties. Protein acetylation refers to the reaction
during which the acetyl group of acetyl coenzyme A (Ac-
CoA) is transferred to the lysine (Lys) residue of the target
protein. HMGB1 has two acetylation clusters at Lys27–
29 and Lys181–183, and it has been shown that nuclear
localization is unaffected by mutating either Lys cluster
(16). The poly(ADP-ribose) polymerase-1 (PARP1) induces
the cytoplasmic translocation and extracellular secretion of
HMGB1 by catalyzing its acetylation (107). Compare to
HMGB1, mimicking acetylated HMGB1 (six lysine residues
for glutamines) increases the TNF-α production in RAW264.7
cells and reduces DC maturation (108). Various triggers
which induces HMGB1 acetylation includes inflammatory
signal such as LPS or TNF-α (109), and cell stress triggered
by chemotherapeutic reagent such as cisplatin (110). Such
conditions can be experimentally mimicked using trichostatin
A (TSA), an inhibitor of histone deacetylase complex
(HDAC) (111).
2) Phosphorylation is a molecular mechanism via which amino
acid residues are phosphorylated by a protein kinase to
regulate the functional response of proteins to various extra-
or intracellular stimuli. HMGB1 phosphorylation is mediated
by classical protein kinase C (cPKC) in a calcium-dependent
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FIGURE 2 | Active secretion and passive release of HMGB1. Summary of stimuli leading to passive HMGB1 release (A) and active HMGB1 secretion (B). (A) Passive
release mechanisms involve the disruption of the plasma membrane via various cell death mechanisms. (B) Active secretion involves various HMGB1
post-translational modifications that reduce its genomic DNA binding activity and increase its CRM1 binding affinity. DAMP, danger-associated molecular pattern;
PAMP, pathogen-associated molecular pattern; PKR, double-stranded RNA-dependent protein kinase; ROS, reactive oxygen species; ATG5, autophagy related 5;
z-VAD, carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]; RIP1, receptor-interacting serine/threonine-protein kinase 1; RIP3, receptor-interacting protein kinase 3;
pMLKL, Phosphorylated mixed linage kinase domain like; PARP1, poly [ADP-ribose] polymerase 1; PCAF, P300/CBP-associated factor.
manner via the PI3K-PKC signaling pathway (14). InHMGB1,
Ser35, 39, 42, and 46 in NLS1, 181 in NLS2, and 53 close to
NLS1 have been shown to be phosphorylated in macrophages
after TNF-α and okadaic acid treatment (15), while Ser39,
53, and 182 of HMGB1 are phosphorylated by PKC-ζ in
colon cancer cells (112). Moreover, HMGB1 phosphorylation
has been found to reduce its binding affinity with the
nuclear import protein KAP-α1 and promote its cytoplasmic
translocation and extracellular secretion (15).
3) ADP-ribosylation refers to the process wherein one or
more ADP-ribose moieties are added to target proteins, and
includes mono-ADP-ribosylation, poly-ADP-ribosylation,
ADP-ribose cyclization, and O-acetyl-ADP-ribose formation.
PARP activation regulates the translocation of HMGB1
from the nucleus to the cytoplasm during DNA-alkylating
damage (103), while hyper poly(ADP)-ribosylated HMGB1
has been shown to inhibit efferocytosis by binding to
phosphatidylserine (PS) on apoptotic cells and RAGE on
macrophages (113). Such activation was reported in cell
death related stimuli such as activation of tumor necrosis
factor [ligand] superfamily member 10 (TNFSF10)—TNF-
related apoptosis-inducing ligand (TRAIL) pathway (114) or
daunorubicin treatment (115), and inflammatory assault with
LPS (103).
4) Methylation is a PTM in which a methyl group is added
to proteins, usually on the side-chain nitrogens of arginine
and lysine or carboxyl groups of glutamate and leucine.
During the process of neutrophilic differentiation, Lys42 in
HMGB1 can be mono-methylated which significantly reduces
its DNA binding activity, causing its translocation from the
nucleus to the cytoplasm (104). Lys112 has also been found
to be mono-methylated in HMGB1 and contribute toward
its cytoplasmic localization (116). However, it is still unclear
which stimuli exclusively leads to the methylation of HMGB1
during active secretion.
5) Glycosylation is a common PTM characterized by the
attachment of sugar moieties to proteins. HMGB1 derived
from calf thymus and chicken erythrocytes undergoes O-
linked GlcNac glycosylation with sugars such as Fuc,
Man, GalNH2, GlcNH2, and Gal monosaccharides (117),
while it has recently been reported that HMGB1 can also
undergo N-linked glycosylation at two consensus (Asn37 and
Asn137) residues and one non-consensus (Asn135) residue.
N-glycosylation of HMGB1, induced by PMA, TSA and
LPS, can persuade its secretion into the extracellular space
by reducing its DNA binding affinity and increasing the
association with CRM1 (105).
6) Oxidation is a covalent modification that proteins undergo
during redox reactions involving the transfer of oxygen,
hydrogen, and electrons. HMGB1 contains three redox-
sensitive cysteines: Cys23, Cys45, and Cys106. Under
mild oxidative stress, Cys23 and Cys45 rapidly form an
intramolecular disulfide bond that increases the cytoplasmic
localization and extracellular secretion of HMGB1 (51). In
response to inflammatory stimuli, PrxI and PrxII induce
HMGB1 oxidation to its disulfide form and lead to its
nucleocytoplasmic translocation and secretion (38). Such
oxidative stresses may come from external sources such
as H2O2 or glucose oxidase, or by internal activation of
molecules by LPS, TNF-α, or interferon-γwhich in turn causes
HMGB1 release through TNF-dependent manner (118). Since
the oxidation status and immunological properties of HMGB1
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crucially influence its biological function, we dedicated
a separate section to discussing HMGB1 redox biology
in detail.
HMGB1 Oxidation Mechanisms
The function and secretion of HMGB1 are dependent on
its redox status, which is controlled by three redox-sensitive
cysteines: Cys23 and Cys45 in A-box and Cys106 in B-box.
Thus, HMGB1 can take three different oxidation forms: an all-
thiol form, disulfide form (Cys23-Cys45 intramolecular disulfide
bond with Cys106 thiol form), and a fully oxidized form. During
the active secretion of HMGB1, the Cys23-Cys45 intramolecular
disulfide bond induces HMGB1 cytoplasmic translocation. This
process also requires Cys106, as demonstrated by the nuclear
localization of Cys106-mutated even with Cys23 and Cys45
mutations (51). Hydrogen peroxide is a ROS that induces the
release of HMGB1 frommacrophages andmonocytes, reportedly
by increasing its interaction with CRM1 and thus increasing
HMGB1 secretion (119). Under elevated ROS conditions, PrxI
and PrxII cause disulfide-HMGB1 formation (38) (Figure 3).
The diversity of HMGB1 redox status also affects its passive
release from necrotic and apoptotic cells, with the majority
of HMGB1 released from necrotic cells being in an all-thiol
state but that released from apoptotic cells being in a fully
oxidized form. Moreover, HMGB1 oxidation status plays an
important role in receptor binding and subsequent cytokine-
like activities.
Hoppe et al. previously described the mechanism of HMGB1
oxidation (51), identifying that HMGB1 interacts with the
de-glutathionylation enzyme glutaredoxin (Grx) during the
nuclear extraction of Chinese hamster ovary (CHO) cells after
diamide treatment. Electrophoretic mobility assays revealed
that HMGB1 oxidation increases in a diamide concentration-
dependent manner, while disulfide-HMGB1 could be reversed
by incubating diamide-treated retinal pigment epithelium (RPE)
cells with thioredoxin (Trx) or Grx/glutathione (Figure 3).
Conversely, we found that HMGB1 can be oxidized by PrxI/II
in the nucleus after exposure to inflammatory stimuli (Figure 3)
(38). PrxI/II can interact with all-thiol-HMGB1 generated
by mutagenesis (Cys23-to-Ser or Cys45-to-Ser) after hydrogen
peroxide stimulation; however, such HMGB1 oxidation is
suppressed in PrxI/II-deficient mouse embryonic fibroblast
FIGURE 3 | HMGB1 redox biology. Summary of HMGB1 redox biology and the crucial role of peroxiredoxin and thioredoxin. Various stimuli cause oxidative stress
that promotes HMGB1 oxidation via the peroxiredoxin-dependent pathway. NADPH, nicotinamide adenine dinucleotide phosphate; SP, peroxidatic cysteine; SR,
resolving cysteine; H, hydrogen; Trx, thioredoxin; TrxR, thioredoxin reductases; NADP, nicotinamide adenine dinucleodebtide phosphate.
Frontiers in Immunology | www.frontiersin.org 7 June 2020 | Volume 11 | Article 1189
Kwak et al. HMGB1 Modification and Redox Biology
(MEF) cells, even when exposed to inflammatory stimuli.
All-thiol-HMGB1 cannot translocate into the cytoplasm or
extracellular space, while PrxI/II-deficient BMDMs lack the
ability to secrete HMGB1 despite treatment with diverse
inflammatory stimuli, such as LPS, phorbol-12-myristate-13-
acetate (PMA), trichostatin A (TSA), or TNF-α (38). HMGB1
phosphorylation by PMA and/or acetylation by TSA promotes
its nuclear transport and extracellular secretion (15, 16).
Although cells treated with PMA or TSA display increased
HMGB1 secretion, this secretion is inhibited by treatment with
the antioxidant N-acetylcysteine (NAC). Moreover, HMGB1
secretion induced by PMA can be inhibited by the NADPH
oxidase inhibitor diphenyleneiodonium (DPI), indicating that
PMA-induced HMGB1 secretion requires H2O2 production
by the mitochondria and/or Nox. Intracellular disulfide bond
formation in HMGB1 (Cys23-Cys45) has been shown to
be important for its nucleocytoplasmic translocation and
extracellular secretion. Indeed, HMGB1 mutants with defective
phosphorylation or acetylation sites undergo less translocation
into the extracellular space than WT HMGB1 (38). In summary,
these findings indicate that the mechanisms of HMGB1
oxidation and reduction are induced by PrxI/II and Trx or
Grx/glutathione, respectively (Figure 3). It is possible that,
like acetylated-HMGB1, oxidized-HMGB1 may be less favored
for nuclear import and thus accumulates in the cytosol.
Oxidized-HMGB1 in the cytosol is packed into lysosomes
through an as yet unknown mechanism and then secreted.
Nevertheless, extracellular HMGB1 can induce an immune
response and HMGB1 oxidation decides its immune function.
Also, as mentioned previously, HMGB1 oxidation has a more
substantial influence on its secretion compared to acetylation
and phosphorylation. Thus, control of HMGB1 oxidation
both in intracellular and extracellular is important for the
therapeutic approach based on blockade of HMGB1 secretion
and immune response.
HMGB1 Secretion Kinetics
The PTMs of HMGB1 in the nucleus occurs rapidly after
exposure to diverse stimuli; however, after binding to CRM1 in
the nucleus, the export of modified HMGB1 into the cytoplasm
is known to take around 6–8 h, whereas it can take up to 18 h
for HMGB1 secretion into the extracellular space to peak. The
degree of HMGB1 oxidation has been reported to be crucial for
its immune function (9, 51, 120) and is also very important for its
secretion. For instance, HMGB1 secretion induced by PTMs such
as phosphorylation or acetylation also requires oxidation, with
anti-oxidant treatment reducing HMGB1 secretion even when
treated with PMA or TSA (38). Therefore, we examined instances
when HMGB1 PTMs and extracellular secretion occur under
oxidative conditions by treating mouse BMDMs with 100 ng/mL
of LPS and separating their nuclei at a series of time points
to determine the HMGB1 oxidation ratio. HMGB1 oxidation
increased with time, with oxidation first detectable after just
30min, and disulfide-HMGB1 was maintained for up to 4 h
and then gradually decreased after 8 h. Despite rapid HMGB1
oxidation in the nucleus, its secretion began only after 4 h and
increased up to 16 h (Figure 4). Further studies investigating
the mechanism underlying the delay between oxidation and
secretionwould improve our understanding ofHMGB1 secretion
kinetics. It is possible that secretion-ready cytosolic HMGB1 is
packed into a secretory lysosome or autophagosome and secreted
via non-conventional secretion mechanisms, requiring a very
complex, as yet unknown, packaging mechanism. Conversely,
a recent article by Wang et al. observed HMGB1 localization
in mitochondria and peroxisome in neuron cells via electron
microscopy and immunofluorescence, but not in lysosomes
(121). In macrophages or macrophage lineages, the release of
HMGB1 occurred through a lysosomal pathway after acetylation
of the HMGB1 (16). It has also been demonstrated that
LPS-induced HMGB1 secretion by monocytes is mediated
by lysosomal exocytosis (106). Various explanations may be
FIGURE 4 | HMGB1 redox kinetics. (A) Short-term (left) and long-term (right) changes of HMGB1 redox status upon LPS stimulation. Western blot showing the
All-thiol-H (all-thiol-HMGB1) or Disulfide-H (disulfide-HMGB1) expression in BMDM whole-cell lysates, which was treated with LPS (100 ng/mL) for indicated times.
Methods were used as our previous study (38). (B) HMGB1 secretion timeframe. Disulfide-H from culture supernatant was measured by Western blot. (C) Graphical
representation of the relationship between HMGB1 oxidation (left y-axis, closed circle) quantified as % maximum from (A) and HMGB1 secretion (right y-axis, opened
circle). The level of secreted HMGB1 was determined by ELISA (38).
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FIGURE 5 | HMGB1 redox status and receptors. Redox status of HMGB1 from various sources with different receptors and their representative functions. Different
redox states are associated with different release mechanisms, each linked to various immunological and cell biological functions.
FIGURE 6 | Current and potential strategies for HMGB1 inhibition. Summary of newly proposed inhibition targets (left), targets utilized by conventional inhibitors (right).
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available for such discrepancy; however, the diverse origin of
cells (macrophage, epithelial, neuronal, etc.) may have different
mechanisms that translocated HMGB1 takes to be secreted to the
extracellular milieu. A complete understanding of the oxidation
kinetics mechanism of HMGB1 is necessary to predict the fate of
HMGB1-mediated inflammation.
HMGB1 Receptors and Immune Functions
As mentioned in the Introduction, extracellular HMGB1 via
active secretion or passive release binds to diverse partners
(Figure 1A). HMGB1 associates and shows interactions with
several molecules, such as Heparin, LPS, LTA, IL-1β, RNA, and
DNA, CXCL12, nucleosomes and C1q (9, 27–30). HMGB1-
partner complex (or HMGB1 alone) interacts with immune
receptors or surface molecules such as TLRs and RAGE,
which then activate the downstream signaling pathways such
as MyD88, IFN regulatory factors (IRFs), nuclear factor κB
(NF-κB), MAPKs and phosphatidylinositol 3-kinase (PI3K) to
enhance the inflammation and immune response (9, 22, 25, 26,
28, 34, 36). Besides, HMGB1 oxidation status alters its receptor
bindings and subsequent cytokine-like activities (9, 51). As
mentioned in section Post-Translational Modifications (PTMs)
and Active Secretion of HMGB1, multiple PTMs are involved in
extracellular secretion of HMGB1. Effect of PTM in receptor-
ligand interaction kinetics between extracellular HMGB1 and
its receptors, however, are understood to a lesser degree. One
example of PTMs positively affecting the HMGB1-receptor
interaction is portrayed using acetylation-mimicking mutant
HMGB1 (six lysine residues for glutamines), increasing TNF-
α production in RAW264.7 cells (108). Thus, although specific
effects for each PTM are yet to be reported, diversely modified
HMGB1 may have an important role in the receptor binding
and downstream signaling pathway. Of all PTMs associated
with HMGB1, only the effects of oxidation are studied in
detail, hence we will focus our scope to the redox status of
extracellular HMGB1 in regards to its activity. HMGB1 binds
to different receptors depending on the redox state of its three
cysteines (C23, C45, C106), which subsequently determines its
functions (120). HMGB1 containing three thiol-form cysteines
exerts chemoattractive effects by forming a heterocomplex
with CXCL12, which then binds to CXCR4 and induces cell
migration. The formation of a complex between HMGB1 and
CXCR4 induces conformational changes in aa residues 3–12
of CXCL12 alongside specific conformational changes in the
CXCR4 homodimer, which promotes better chemotactic abilities
than CXCL12 alone (32). All-thiol-HMGB1 can also bind to
RAGE and promote autophagy (122) by inhibiting mTOR
and promoting Beclin 1-Ptdlns3KC3 complex formation (123).
ROS induces HMGB1 oxidation and cytosolic translocation
from the nucleus. Cytoplasmic HMGB1 binds to Beclin 1
using an intramolecular disulfide bridge (Cys23 and Cys45) to
enhance autophagic flux (37, 124, 125). Moreover, the interaction
between HMGB1 and RAGE activates NF-κB, the MAP kinase
pathways and affects cell migration by inducing the expression
of adhesion molecules (126, 127). Extracellular HMGB1 can
also stimulate RAGE expression (128). Conversely, disulfide-
HMGB1 stimulates cytokine production and inflammation by
forming a complex with CD14 andMD-2 via TLR4. The disulfide
bond between C23-C45 and the thiol form of C106 residues
are not only required for binding TLR4 but also inducing the
translocation of NF-κB and release of TNF-α (48). These findings
were confirmed in apoptotic cells where fully oxidized-HMGB1
produced by excessive ROS contributed toward immunological
inertness and apoptotic cell death (32). Although its specific
functions remain unclear, fully oxidized-HMGB1 is known to
prevent the cytokine or chemokine activities of other HMGB1
forms and ultimately induce immune tolerance (32) (Figure 5).
In contrast, CD24-Siglec-10 and TIM-3 are negative receptors
that inhibit HMGB1 immune activity in macrophages, DCs
and tumor cells. HMGB1 can bind to CD24, first identified
as a B cell differentiation marker, and selectively represses
the tissue damage-induce inflammation through induction of
CD24-Siglec-10 complex formation, negatively regulating NF-
κB (36). Also, HMGB1 can bind to TIM-3, a member of
the T-cell immunoglobulin domain and mucin domain family,
and its binding suppresses the nucleic acid-mediated antitumor
immunity via A-box competing with nucleic acid (26). The
aforementioned reports indicate extracellular HMGB1 have not
only pro-inflammatory effects but also anti-inflammatory effects
according to the microenvironment.
Extracellular HMGB1 not only differ in functions by its
PTM derivations, but also by the types of cells responding to
HMGB1. Monocytes exposed to HMGB1 polarized toward pro-
inflammatory (M1) macrophages, upregulating the production
of inflammatory cytokines both in vitro and in vivo (129, 130).
Silencing of HMGB1, on the other hand, prevents macrophage
polarization to the M1 phenotype following LPS stimulation
(131). Similarly, neutrophils react to extracellular HMGB1 by
promoting its neutrophil extracellular trap formation (132) and
heighten its immune reactions (133). DCs consider HMGB1 as
an endogenous adjuvant to boost its effectiveness in antigen-
presenting to its adaptive counterparts (134). Extracellular
HMGB1, as discussed above, has exhibited significance in various
immunological and physiological contexts, sparking an interest
in suppressing its functions. Controlling HMGB1 as a potential
therapeutic target in the immune diseases must be exquisitely
controlled depending on its purpose.
HMGB1 Inhibition
The involvement of HMGB1 in various pathologies ranging from
inflammatory diseases to cancer has been discussed thoroughly
and has resulted in the development of HMGB1 secretion
inhibitors. Currently, several companies and research centers
sought to control the effects of HMGB1 by modulating its
expression, translocation, secretion, and receptor binding ability
using diverse chemicals as an approach to develop therapeutic
agents. These strategies for suppressing HMGB1 secretion can
be divided into three categories: (1) small molecules inhibiting
HMGB1 release; (2) neutralizing HMGB1 itself; and (3) blocking
HMGB1 receptors (Figure 6).
Numerous studies have reported small molecules capable of
inhibiting HMGB1 secretion, from newly synthesized molecules
to those isolated from natural sources. For instance, naturally
isolated small molecules such as glycyrrhizin have been reported
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to be effective in treating numerous pathological conditions,
such as septic shock, neuroinflammation, atopic dermatitis, and
Pseudomonas aeruginosa keratitis (135–138). Syntheticmolecules
such as ethyl pyruvate, atorvastatin, and simvastatin have
also demonstrated promising therapeutic activity by targeting
HMGB1. In addition, the natural flavonoid kaempferol was
found to alleviate neuroinflammation by suppressing HMGB1
release and down regulating the TLR4/MyD88 pathway (139),
and the rare ginsenosides Rk1 and Rg5 have shown promise
by reducing HMGB1 release and thereby improving survival
in cecum ligation- and puncture-induced murine sepsis models
(140). Inflachromene, a novel small molecule developed as a
potential anti-inflammatory drug, was also found to inhibit
HMGB1 secretion via directly binding to HMGB1 and inhibiting
autophagy (141, 142). Despite most of the candidates are yet
to be approved by the Food and Drug Administration (FDA),
Metformin, clinically approved drug for metabolic disease and
type 2 diabetes, has investigated as an inhibitor for HMGB1
through direct binding each other, inhibiting the cytosolic
translocation within the cells and receptor binding in the
extracellular space (143, 144). Other candidates of HMGB1
secretion inhibitors are also being discovered through drug
repositioning efforts, such as salicylic acid, methotrexate, and
(-)-epigallocatechin-3-gallate (145–147).
Neutralizing antibodies against HMGB1 have been used to
confirm its involvement in mouse models of various pathologies,
such as arthritis, suggesting that HMGB1-neutralizing antibodies
could be used therapeutically (148, 149). Indeed, neutralizing
the effects of HMGB1 by competitively inhibiting its activity
with soluble receptors or neutralizing antibodies could be a
straightforward and approach. A soluble form of RAGE was
reported to effectively reduce neutrophilic asthma attacks and
angiotensin II-induced cardiomyocyte hypertrophy by inhibiting
the HMGB1-RAGE axis (150, 151). Similarly, studies have
reported the inhibition of the HMGB1-receptor signaling
pathway using neutralizing antibodies against its receptors.
For instance, neutralizing monoclonal antibodies recognizing
TLR4 were used to reduce IL-8 secretion upon LPS stimulation
in human primary monocytes, and efforts to use HMGB1
neutralizing antibodies in stroke patients are being continually
made (152, 153). Moreover, the continual administration
of neutralizing antibodies against RAGE in murine models
of neurological pain were reported to reverse mechanical
hyperalgesia (154, 155) Further information about HMGB1
inhibitors could be found in this Frontiers Research Topics of
“The Role of HMGB1 in Immunity” by Yang et al. (156).
We suggest expanding on the importance of modulating the
HMGB1 oxidation mechanism. HMGB1 oxidation is the major
PTM that drives secretion and its oxidized form of extracellular
HMGB1 induce inflammatory signaling, which leads to many
diseases, including neuroinflammation, hyperalgesia, drug-
induced liver injury, and sepsis (157–159). Of particular note is
the fact that it is important to develop specific inhibitors targeting
the enzymes involved in altering HMGB1 redox status. Prx,
which is a major direct modulator of HMGB1 redox status, could
possibly be a plausible candidate for inhibition (38), whereas
well-established redox enzymes with a strong connection to Prx,
such as Trx and sulforedoxins, could also be potential targets for
inhibition (160) (Figure 6).
CONCLUDING REMARKS
Although several strategies have been shown successfully in
inhibiting HMGB1-dependent inflammatory processes (156),
there is still a lack of specificity originating from HMGB1’s
involvement in pathologies. This review aims to overcome the
aforementioned weak points by suggesting various plausible
aspects of inhibition, increasing the specificity of inhibition
therapies. We provide an overview of the protein secretion
mechanisms and discuss the HMGB1 secretion mechanisms
and pathways in depth. Besides, we highlight the importance
of multiple PTMs and the redox biology of HMGB1, with a
particular focus on the important role of HMGB1 oxidation
in its secretion. Finally, we discuss multiple immunological
and non-immunological diseases involving HMGB1, as well
as attempts to inhibit its secretion, extracellular activity, or
the receptors that bind to HMGB1. The next step should to
unveil fine-tuned process of HMGB1 PTMs in physiological
and pathological conditions. Future researches would benefit
from extensive quantitative analysis of extracellular HMGB1
and its PTM patterns in various cell types and different
pathological conditions to further develop disease-specific
inhibition strategies.
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